^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3 I836

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    11ms
    LACEWING: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy (clinicaltrials.gov)
    P3, N=183, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • azacitidine
    1year
    ADMIRAL: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation (clinicaltrials.gov)
    P3, N=371, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    over1year
    Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study. (PubMed, Int J Mol Sci)
    We also examined the effects of I836 variants on binding affinity to sorafenib using molecular docking...Many single-nucleotide variations in FLT3 have an impact on its structure and function. Thus, the annotation of FLT3 SNVs and the prediction of their deleterious pathogenic impact will facilitate an insight into the tumorigenesis process and guide experimental studies and clinical implications.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand)
    |
    FLT3 I836
    |
    sorafenib
    almost2years
    FRIDA: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (clinicaltrials.gov)
    P1, N=50, Recruiting, Oryzon Genomics S.A. | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • iadademstat (ORY-1001)
    almost2years
    OGILAR: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=33, Recruiting, French Innovative Leukemia Organisation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • Onureg (azacitidine oral)
    2years
    Persistence of FLT3-TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission (ASH 2023)
    Detectable persistence of FLT3-TKD variants in blood from AML patients in first remission prior to first alloHCT is rare, but at a VAF level of 0.1% was strongly associated with increased relapse and death after transplant compared to those testing negative. In contrast to FLT3-ITD NGS-MRD, no evidence was found to support lowering the NGS-MRD VAF threshold from 0.1% to 0.01% for FLT3-TKD. Alternative methodology may further improve NGS-MRD test performance.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • FLT3 D835 • FLT3 I836
    over2years
    OGILAR: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, French Innovative Leukemia Organisation
    New P2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • Onureg (azacitidine oral)
    over2years
    ADMIRAL: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation (clinicaltrials.gov)
    P3, N=371, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Jul 2023 --> Jul 2024
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    over2years
    COMMODORE: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation (clinicaltrials.gov)
    P3, N=276, Active, not recruiting, Astellas Pharma Inc | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Feb 2024
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV
    over2years
    How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication? (PubMed, Cancer Drug Resist)
    A class of drugs, tyrosine-kinase inhibitors (TKI), targeting mutated FLT3, is already available with 1 and 2 generation molecules, but only midostaurin and gilteritinib are currently approved...Indeed, FLT3 inhibitors have significantly contributed to reducing the negative impact of FLT3 mutations on the prognosis of AML patients who are no longer considered at high risk by the European LeukemiaNet (ELN) 2022. Finally, several ongoing efforts to overcome resistance to FLT3-inhibitors will be presented: new generation FLT3 inhibitors in monotherapy or combined with standard chemotherapy, hypomethylating drugs, or IDH1/2 inhibitors, Bcl2 inhibitors; novel anti-human FLT3 monoclonal antibodies (e.g., FLT3/CD3 bispecific antibodies); FLT3-CAR T-cells; CDK4/6 kinase inhibitor (e.g., palbociclib).
    Review • Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Ibrance (palbociclib) • sorafenib • Xospata (gilteritinib) • midostaurin • Vanflyta (quizartinib) • crenolanib (ARO-002)
    over2years
    LACEWING: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy (clinicaltrials.gov)
    P3, N=183, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2023 --> Jun 2024
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • azacitidine